402 related articles for article (PubMed ID: 37457699)
1. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
Hu C; Liu M; Li Y; Zhao Y; Sharma A; Liu H; Schmidt-Wolf IGH
Front Immunol; 2023; 14():1213716. PubMed ID: 37457699
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.
Qureshi HA; Lee SM
Curr Treat Options Oncol; 2019 Mar; 20(4):31. PubMed ID: 30874960
[TBL] [Abstract][Full Text] [Related]
3. Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.
Haist C; Poschinski Z; Bister A; Hoffmann MJ; Grunewald CM; Hamacher A; Kassack M; Wiek C; Scheckenbach K; Hanenberg H
Oral Oncol; 2022 Jun; 129():105867. PubMed ID: 35468475
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
[TBL] [Abstract][Full Text] [Related]
5. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
[TBL] [Abstract][Full Text] [Related]
6. CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head/neck squamous cell carcinoma cells.
Haist C; Schulte E; Bartels N; Bister A; Poschinski Z; Ibach TC; Geipel K; Wiek C; Wagenmann M; Monzel C; Scheckenbach K; Hanenberg H
Oral Oncol; 2021 May; 116():105259. PubMed ID: 33895463
[TBL] [Abstract][Full Text] [Related]
7. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
8. Head and neck cancer treatment in the era of molecular medicine.
Pandruvada S; Kessler R; Thai A
Adv Cancer Res; 2023; 160():205-252. PubMed ID: 37704289
[TBL] [Abstract][Full Text] [Related]
9. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
[TBL] [Abstract][Full Text] [Related]
10. Tumor immune microenvironment in head and neck cancers.
Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
[TBL] [Abstract][Full Text] [Related]
11. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.
Park YP; Jin L; Bennett KB; Wang D; Fredenburg KM; Tseng JE; Chang LJ; Huang J; Chan EKL
Oral Oncol; 2018 Mar; 78():145-150. PubMed ID: 29496042
[TBL] [Abstract][Full Text] [Related]
12. Novel technologies for improving the safety and efficacy of CAR-T cell therapy.
Ohta K; Sakoda Y; Tamada K
Int J Hematol; 2023 May; 117(5):647-651. PubMed ID: 36309630
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
14. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
[TBL] [Abstract][Full Text] [Related]
15. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
17. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
18. Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ; Lee YH; Koo KC
Investig Clin Urol; 2022 Sep; 63(5):486-498. PubMed ID: 36067994
[TBL] [Abstract][Full Text] [Related]
19. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
Wang H; Pan W
Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
